Journal
NATURE COMMUNICATIONS
Volume 13, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-022-29911-3
Keywords
-
Categories
Funding
- ZONMW, the Netherlands [10430062010001]
- Fight AIDS and Infectious Diseases Foundation
- Grifols S.A
- Hospital Universitari Germans Trias i Pujol
- Banc de Sang i Teixits de Catalunya (BST)
- Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program [CEX2018-000806-S]
- Generalitat de Catalunya through the CERCA Program
- Government of Mozambique
- Spanish Agency for International Development (AECID)
- Government of Catalonia's Secretariat for Universities and Research
- Marie Sklodowska-Curie Actions COFUND Program (BP3) [801370]
- National Agency for Research and Development of Chile (ANID) [72180406]
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program ZONMW, the Netherlands [10430062010001]
- SUPPORT-E [101015756]
- crowd funding campaign YoMe Corono
Ask authors/readers for more resources
This study assessed whether convalescent plasma (CP) administered during the first week of symptoms reduced disease progression or risk of hospitalization in COVID-19 outpatients. The results showed that CP had no significant impact on disease severity scale and hospitalization or death, but may have some effect in patients with symptoms lasting <= 5 days. Additionally, CP did not shorten the time to full symptom resolution.
Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of recruitment target was achieved. A Bayesian-adaptive individual patient data metaanalysis was implemented. Outpatients aged >= 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available